Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier:: role of myosin light-chain kinase protein expression

被引:384
作者
Ma, TY
Boivin, MA
Ye, DM
Pedram, A
Said, HM
机构
[1] Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Long Beach Vet Affairs Med Ctr, Dept Med, Irvine, CA USA
[4] Albuquerque Vet Affairs Med Ctr, Albuquerque, NM USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2005年 / 288卷 / 03期
关键词
intestinal permeability; tight junctions; intestinal barrier;
D O I
10.1152/ajpgi.00412.2004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
TNF-alpha plays a central role in the intestinal inflammation of various inflammatory disorders including Crohn's disease (CD). TNF-alpha-induced increase in intestinal epithelial tight junction (TJ) permeability has been proposed as one of the proinflammatory mechanisms contributing to the intestinal inflammation. The intracellular mechanisms involved in the TNF-alpha-induced increase in intestinal TJ permeability remain unclear. The purpose of this study was to investigate the possibility that the TNF-alpha-induced increase in intestinal epithelial TJ permeability was regulated by myosin light-chain kinase (MLCK) protein expression, using an in vitro intestinal epithelial model system consisting of the filter-grown Caco-2 intestinal epithelial monolayers. TNF-alpha (10 ng/ml) produced a time-dependent increase in Caco-2 MLCK expression. The TNF-alpha increase in MLCK protein expression paralleled the increase in Caco-2 TJ permeability, and the inhibition of the TNF-alpha-induced MLCK expression (by cycloheximide) prevented the increase in Caco-2 TJ permeability, suggesting that MLCK expression may be required for the increase in Caco-2 TJ permeability. The TNF-alpha increase in MLCK protein expression was preceded by an increase in MLCK mRNA expression but not an alteration in MLCK protein degradation. Actinomycin-D prevented the TNF-alpha increase in MLCK mRNA expression and the subsequent increase in MLCK protein expression and Caco-2 TJ permeability, suggesting that the increase in MLCK mRNA transcription led to the increase in MLCK expression. The TNF-alpha increase in MLCK protein expression was also associated with an increase in Caco-2 MLCK activity. The cycloheximide inhibition of MLCK protein expression prevented the TNF-alpha increase in MLCK activity and Caco-2 TJ permeability. Moreover, inhibitors of MLCK, Mg2+-myosin ATPase, and metabolic energy prevented the TNF-alpha increase in Caco-2 TJ permeability, suggesting that the increase in MLCK activity was required for the TNF-alpha-induced opening of the Caco-2 TJ barrier. In conclusion, our results indicate for the first time that 1) the TNF-alpha increase in Caco-2 TJ permeability was mediated by an increase in MLCK protein expression, 2) the increase in MLCK protein expression was regulated by an increase in MLCK mRNA transcription, and 3) the increase in Caco-2 TJ permeability required MLCK protein expression-dependent increase in MLCK activity.
引用
收藏
页码:G422 / G430
页数:9
相关论文
共 48 条
[1]   REGULATION AND KINETICS OF THE ACTIN-MYOSIN-ATP INTERACTION [J].
ADELSTEIN, RS ;
EISENBERG, E .
ANNUAL REVIEW OF BIOCHEMISTRY, 1980, 49 :921-956
[2]  
ALLEN U, 1986, DIGEST DIS SCI, V32, P100
[3]   TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION [J].
BRAEGGER, CP ;
NICHOLLS, S ;
MURCH, SH ;
STEPHENS, S ;
MACDONALD, TT .
LANCET, 1992, 339 (8785) :89-91
[4]   Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial [J].
Ehrenpreis, ED ;
Kane, SV ;
Cohen, LB ;
Cohen, RD ;
Hanauer, SB .
GASTROENTEROLOGY, 1999, 117 (06) :1271-1277
[5]  
Felder JB, 2000, AM J GASTROENTEROL, V95, P1949
[6]   Stress-induced disruption of colonic epithelial barrier:: Role of interferon-γ and myosin light chain kinase in mice [J].
Ferrier, L ;
Mazelin, L ;
Cenac, N ;
Desreumaux, P ;
Janin, A ;
Emilie, D ;
Colombel, JF ;
Garcia-Villar, R ;
Fioramonti, J ;
Bueno, L .
GASTROENTEROLOGY, 2003, 125 (03) :795-804
[7]  
Gitter AH, 2000, ANN NY ACAD SCI, V915, P193
[8]   Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].
Hanauer, SB ;
Feagan, BG ;
Lichtenstein, GR ;
Mayer, LF ;
Schreiber, S ;
Colombel, JF ;
Rachmilewitz, D ;
Wolf, DC ;
Olson, A ;
Bao, WH ;
Rutgeerts, P .
LANCET, 2002, 359 (9317) :1541-1549
[9]   CLOSTRIDIUM-DIFFICILE TOXIN-B DISRUPTS THE BARRIER FUNCTION OF T84 MONOLAYERS [J].
HECHT, G ;
KOUTSOURIS, A ;
POTHOULAKIS, C ;
LAMONT, JT ;
MADARA, JL .
GASTROENTEROLOGY, 1992, 102 (02) :416-423
[10]  
HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736